Stay updated on Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.

Latest updates to the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page
- Check5 days agoChange DetectedNo significant changes were detected in the Study Details page for NCT03854474. The content and layout appear unchanged aside from routine metadata such as the last update timestamp.SummaryDifference0.3%

- Check12 days agoNo Change Detected
- Check34 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference2%

- Check41 days agoChange DetectedUpdated the page from Revision: v3.0.2 to Revision: v3.1.0, signaling a new release version.SummaryDifference0.0%

- Check55 days agoChange DetectedUpdated to Revision: v3.0.2 (from v3.0.1); the 'Back to Top' element has been removed.SummaryDifference0.1%

- Check62 days agoChange DetectedThe webpage has been updated to reflect a new version and the addition of a Diagnostic CAT Scan service type, while previous update dates and version information have been removed.SummaryDifference0.6%

- Check70 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new medical terms related to bladder cancer and diagnostic techniques. Notably, the previous version's references to certain cancer treatments and genetic resources have been removed.SummaryDifference2%

Stay in the know with updates to Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.